You are viewing: UAE Multiomics Market analysis
Part of: Multiomics Market (Global)

The UAE Multiomics Market was valued at $11.9 Million in 2026 and projected to reach to $18.3 Million by 2031, representing a compound annual growth rate of CAGR 9.0%. The UAE multiomics market is experiencing steady expansion as healthcare providers increasingly integrate genomics, proteomics, and metabolomics into clinical practice.

UAE Multiomics Market (2026-2031) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

UAE Multiomics Market Trends and Insights

  • This 9.0% compound annual growth rate reflects UAE's strategic investments in precision medicine and advanced diagnostic technologies.
  • The UAE's commitment to healthcare modernization, coupled with government initiatives supporting biotechnology research and development, is driving adoption of multiomics solutions across clinical and research institutions. UAE's multiomics market benefits from the nation's robust healthcare infrastructure, high per capita spending on medical innovation, and increasing prevalence of chronic diseases requiring advanced diagnostic approaches.
  • Between 2026 and 2031, the UAE is expected to see accelerated integration of genomics, proteomics, and metabolomics platforms in hospitals and diagnostic centers.
  • The market's growth trajectory reflects UAE's positioning as a regional hub for healthcare technology adoption and its emphasis on personalized medicine as a cornerstone of future clinical practice..

Key Market Statistics

  • CAGR (2026-2031) CAGR 9.0%
  • Market Size, 2026 ~USD 11.9 Million
  • Forecast, 2031 ~USD 18.3 Million
  • Country UAE

UAE Multiomics Market Overview

Market Valuation Growth :

UAE's multiomics market is valued at USD 11.9 million in 2026, with projections reaching USD 18.3 million by 2031, representing a robust 9.0% CAGR driven by precision medicine adoption.

Government Healthcare Modernization :

UAE's strategic investments in advanced diagnostic technologies and precision medicine initiatives position the nation as a regional leader in multiomics innovation and implementation.

GCC Regional Significance :

The UAE multiomics market serves as a critical growth segment within the broader GCC healthcare landscape, attracting regional and international healthcare stakeholders.

Precision Medicine Integration :

Growing adoption of multiomics solutions in UAE healthcare facilities supports personalized treatment approaches and enhanced diagnostic accuracy across major medical centers.

UAE Multiomics Market Dynamics

  • Government support for healthcare digitalization and precision medicine initiatives creates a favorable environment for market growth.
  • The 9.0% CAGR reflects UAE's commitment to adopting cutting-edge diagnostic technologies and establishing itself as a regional hub for advanced healthcare solutions.
  • Investment in research infrastructure and partnerships with global biotech firms further accelerate market penetration. Looking ahead to 2031, the UAE multiomics market will benefit from rising healthcare expenditure, growing patient awareness, and regulatory frameworks supporting precision medicine adoption.
  • The expansion of diagnostic laboratories and integration of multiomics into routine clinical workflows will drive demand.
  • Additionally, UAE's vision to become a global healthcare innovation center positions multiomics as a strategic priority, ensuring sustained market growth and attracting international investment in the sector..

Market Ecosystem

logo-mobile

MULTIOMICS MARKET: COMMERCIAL USE CASES ACROSS INDUSTRIES

COMPANY USE CASE DESCRIPTION BENEFITS
company logo
Provides Illumina Connected Multiomics, a cloud-based platform that integrates and analyzes genomics, transcriptomics, proteomics, epigenomics, and other multiomic datasets. For example, oncology researchers at the University of Colorado Anschutz Medical Campus used the platform to analyze proteomic data and generate insights into melanoma biology. Enables integrated analysis of multiple biological data layers, helping researchers identify biomarkers, understand disease mechanisms, and accelerate precision medicine and drug discovery. (Illumina)
company logo
Provides Chromium Single Cell Multiome ATAC + Gene Expression technology, enabling simultaneous profiling of chromatin accessibility and gene expression in individual cells. Its platforms are widely used in cancer, immunology, and developmental biology research to characterize cellular states and regulatory mechanisms. Provides a comprehensive view of gene regulation at single-cell resolution, helping researchers link regulatory elements with gene expression and identify disease-associated cell populations.

Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.

Related Ecosystem

Biotechnology

Top Technologies
  • Reagents
  • Polymerase Chain Reaction (PCR)
  • Stem Cells
  • Assay Kits
  • Flow Cytometers
Top Companies
  • Thermo Fisher Scientific Inc.
  • Merck KGaA
  • Danaher Corporation
  • Agilent Technologies, Inc.
  • Bio-Rad Laboratories, Inc.

    Key Takeaways

    • UAE's multiomics market is valued at USD 11.9 million in 2026, expanding at a 9.0% CAGR through 2031.
    • The UAE's advanced healthcare infrastructure and government support for precision medicine are primary growth catalysts.
    • By 2031, UAE's multiomics market is forecast to reach USD 18.3 million, reflecting strong regional demand.
    • UAE's positioning as a GCC healthcare innovation hub accelerates adoption of integrated genomic and proteomic diagnostics.

    Multiomics Market Report Scope

    Report Metric Details
    Base Year 2026
    Fastest Growing Segment SERVICES (Offering)
    Forecast Period 2026-2031
    Growth Rate CAGR of 12.3% from 2026 to 2031
    Largest Segment PRODUCTS (Offering)
    Market Size Base Year (Billions) ~USD 3.19 (2026)
    Revenue Forecast (Billions) ~USD 5.7 (2031)
    Segments Covered Offering, Type, Technology, Method, Workflow, Application, End User

    UAE Multiomics Market Report Segmentation

    7 segment dimensions are covered across the global market.

    By Offering

    • Products
    • Services

    By Type

    • Assay Kits & Reagents
    • Consumables
    • Instruments & Software
    • Long-Read Sequencing
    • Ms-Based Proteomics
    • Nanopore Sequencing
    • Ngs-Based Proteomics
    • Other Consumables
    • Other Proteomics Methods
    • Other Sequencing Technologies
    • Pcr-Based Proteomics
    • Smrt Sequencing

    By Technology

    • Long-Read Sequencing
    • Nanopore Sequencing
    • Other Sequencing Technologies
    • Other Technologies
    • Proteomics
    • Sequencing
    • Smrt Sequencing

    By Method

    • Chromatin Accessibility Sequencing
    • Chromatin Interaction Analysis
    • Dna Methylation Sequencing
    • Epigenomics
    • Histone Modification Profiling
    • Long-Range Sequencing
    • Long-Read & Long-Range Sequencing
    • Long-Read Sequencing
    • Ms-Based Proteomics
    • Ngs-Based Proteomics
    • Other Epigenomics Methods
    • Other Long-Read & Long-Range Sequencing Methods
    • Other Methods
    • Other Proteomics Methods
    • Other Single-Cell Omics
    • Other Spatial Omics
    • Pcr-Based Proteomics
    • Proteomics
    • Sequencing-Based Epigenomics
    • Single-Cell Epigenomics
    • Single-Cell Genomics
    • Single-Cell Omics
    • Single-Cell Proteomics
    • Single-Cell Transcriptomics
    • Spatial Epigenomics
    • Spatial Genomics
    • Spatial Omics
    • Spatial Proteomics
    • Spatial Transcriptomics

    By Workflow

    • Data Visualization & Analysis
    • Sample Preparation
    • Sequencing & Analysis/ Sample Characterization
    • Sequencing & Analysis/Sample Characterization

    By Application

    • Biomarker Discovery
    • Cell Biology
    • Clinical Diagnostics
    • Drug Discovery & Development
    • Immunology
    • Neurology
    • Oncology
    • Other Applications
    • Precision Medicine
    • Translational Research

    By End User

    • Academic & Research Institutes
    • Cros & Cdmos
    • Hospitals & Diagnostic/Clinical Laboratories
    • Pharmaceutical & Biotechnology Companies

    Target Audience

    • Healthcare Providers & Hospitals : UAE-based hospitals and diagnostic centers need market insights to evaluate multiomics integration, assess competitive offerings, and plan precision medicine service expansion.
    • Biotech & Diagnostics Companies : International and regional biotech firms require UAE-specific market data to assess market entry feasibility, identify growth opportunities, and develop localized product strategies.
    • Healthcare Investors & PE Firms : Investment firms targeting UAE healthcare sector need detailed market forecasts and growth drivers to evaluate investment opportunities in multiomics and precision medicine ventures.
    • Government & Healthcare Authorities : UAE health ministries and regulatory bodies utilize market intelligence to inform healthcare policy, allocate resources for precision medicine initiatives, and support innovation ecosystems.
    • Medical Device & IT Solution Providers : Technology vendors need UAE market insights to develop compatible multiomics platforms, understand adoption barriers, and align solutions with local healthcare infrastructure requirements.

    Reasons to Buy this Report

    • Market-Specific Growth Projections : Access detailed UAE market forecasts from USD 11.9M (2026) to USD 18.3M (2031), enabling accurate business planning and investment decisions tailored to the local market trajectory.
    • Competitive Landscape Intelligence : Understand UAE-specific market dynamics, key players, and competitive positioning within the GCC region to identify partnership and expansion opportunities in precision medicine.
    • Government Policy & Regulatory Insights : Gain clarity on UAE's healthcare modernization initiatives, precision medicine policies, and regulatory frameworks that directly impact multiomics market entry and operational strategies.
    • Investment & Expansion Strategy : Leverage UAE market data to develop targeted go-to-market strategies, identify high-potential segments, and optimize resource allocation for healthcare technology providers and diagnostics firms.
    • Regional Hub Positioning : Capitalize on UAE's strategic position as a GCC healthcare innovation center to establish regional headquarters, distribution networks, and partnerships for multiomics solutions across the Middle East.

    Frequently asked questions

    What is the current size of the UAE multiomics market?

    The UAE multiomics market is valued at USD 11.9 million in 2026, representing a significant segment within the GCC healthcare sector.

    What is the projected market size for UAE multiomics by 2031?

    The UAE multiomics market is forecast to reach USD 18.3 million by 2031, growing at a 9.0% CAGR from 2026.

    What factors are driving growth in the UAE multiomics market?

    UAE's multiomics market growth is driven by government healthcare modernization initiatives, high medical spending, advanced diagnostic infrastructure, and increasing adoption of precision medicine approaches.

    How does the UAE multiomics market compare to other GCC countries?

    The UAE represents a leading market within the GCC for multiomics adoption, supported by its advanced healthcare ecosystem and strategic positioning as a regional innovation hub.

    Which applications are most prominent in the UAE multiomics market?

    Clinical diagnostics, oncology research, and personalized medicine applications are among the most prominent use cases driving UAE's multiomics market expansion.

    RESEARCH METHODOLOGY

    This study involved four major activities in estimating the current size of the multiomics market. Exhaustive secondary research was conducted to gather information on the market, its peer markets, and its parent market. These findings, assumptions, and sizing were then validated with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. Following this, the data triangulation procedure was used to estimate the market size of segments and subsegments.

    Secondary Research

    Secondary research was primarily used to identify and gather information for the extensive, technical, market-oriented, and commercial study. The secondary sources referred for this research study include publications from government sources, such as the National Institutes of Health (NIH), National Center for Biotechnology Information (NCBI), European Bioinformatics Institute (EMBL-EBI), US Food and Drug Administration (FDA), European Medicines Agency (EMA), World Health Organization (WHO), and Organisation for Economic Co-operation and Development (OECD). Omics-specific repositories and research initiatives, including Human Protein Atlas, the Cancer Genome Atlas (TCGA), Genotype-Tissue Expression (GTEx), Clinical Proteomic Tumor Analysis Consortium (CPTAC), among several others. Secondary sources also included corporate and regulatory filings (such as annual reports, SEC filings, investor presentations, and financial statements); business magazines and research journals; press releases; and trade, business, and professional associations. These sources were also used to obtain key information on major players, global product revenues, market classification, and segmentation by industry trends, regional/country-level markets, market developments, and technology perspectives. Secondary data were collected and analyzed to determine the overall size of the global Multiomics market, and the findings were validated through primary research.

    Primary Research

    In-depth interviews were conducted with primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among others, to obtain and verify critical qualitative and quantitative information and assess market prospects. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information. The following is a breakdown of the primary respondents:

    Multiomics Market Size, and Share

    To know about the assumptions considered for the study, download the pdf brochure

    Market Size Estimation

    The global size of the multiomics market was estimated through multiple approaches. A detailed market estimation approach was used to estimate and validate the market value and other dependent submarkets. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

    Multiomics Market : Top-Down and Bottom-Up Approach

    Multiomics Market Top Down and Bottom Up Approach

    Data Triangulation

    After estimating the overall market size from the market size estimation process, the total market was split into several segments. To complete the overall market engineering process and arrive at the exact statistics for all segments, the data triangulation procedure was employed; it involved studying various factors and trends from both the demand and supply sides.

    Market Definition

    The multiomics market comprises commercial revenues generated from products and services used to perform integrated multiomics analyses by combining two or more molecular profiling modalities, such as genomics, epigenomics, transcriptomics, proteomics, and spatial or single-cell omics. The market includes instruments, software, assay kits, reagents, consumables, and analytical services supporting advanced multiomics workflows from sample preparation and molecular characterization to data integration, visualization, and interpretation. These technologies are used across research and clinical applications, including oncology, precision medicine, biomarker discovery, translational research, drug discovery, and clinical diagnostics, by pharmaceutical and biotechnology companies, academic and research institutions, hospitals, diagnostic laboratories, CROs, and CDMOs. The market excludes conventional single-omics technologies, routine short-read sequencing workflows, microarray-based molecular profiling, and general laboratory products not specifically designed for integrated multiomics applications.

    Key Stakeholders

    • Multiomics product & service providers
    • Multiomics bioinformatics/data analysis companies
    • Venture capitalists and other government funding organizations
    • Research and consulting firms
    • Hospitals and diagnostic clinics
    • Pharmaceutical and biotechnology companies
    • Academic and government research institutes
    • Life science companies

    Report Objectives

    • To define, describe, and forecast the multiomics market by offering, method, technology, workflow, application, end user, and region
    • To provide detailed information regarding the major factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
    • To analyze the micromarkets with respect to individual growth trends, prospects, and contributions to the overall multiomics market
    • To analyze the opportunities for stakeholders and provide details of the competitive landscape for market leaders
    • To forecast the size of the market segments with respect to six regions: North America (US and Canada), Europe (Germany, France, the UK, Italy, Spain, and the Rest of Europe), Asia Pacific (China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific), Latin America (Brazil, Mexico, Argentina, and the Rest of Latin America), the Middle East [GCC Countries (Saudi Arabia (KSA), United Arab Emirates (UAE), and the Rest of GCC Countries) and the Rest of Middle East], and Africa
    • To profile the key players and analyze their market shares and core competencies
    • To track and analyze competitive developments, such as product launches, partnerships, agreements, collaborations, and expansions
    • To benchmark players within the market using the proprietary “Company Evaluation Matrix” framework, which analyzes market players on various parameters within the broad categories of business and product excellence strategy

    Available customizations:

    With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the report:

    Geographical Analysis

    • Further breakdown of the Rest of Europe multiomics market, by country
    • Further breakdown of the Rest of Asia Pacific multiomics market, by country

    Company Analysis

    • Detailed analysis and profiling of additional market players (up to five)

    Segment Analysis

    • Cross-segment analysis

    Get the Full Multiomics Market Report

    Full forecast, segment splits, and company analysis for all Multiomics Market.

    Need a Tailored Report?

    Customize this report to your needs

    Get 10% FREE Customization

    Customize This Report
    Fact checked
    DMCA.com Protection Status